Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
Checked against the public recordLast updated Oct 12, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Inclusion Criteria: * ECOG Performance Status (PS) \<=1 * Histologically or cytologically confirmed, stage IIIB (malignant pleural effusion), stage IV or recurrent NSCLC * Measurable disease by RECIST guidelines Exclusion Criteria: * Evidence of predominantly squamous-cell histology * Known CNS metastases * Any prior antineoplastic systemic regimens for NSCLC * Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident * Gross hemoptysis (≥1/2 tsp of red blood) * Uncontrolled hypertension * Clinically significant cardiovascular disease * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Acrc/Arizona Clinical Research Center, Inc.Tucson, Arizona
- Sharp Clinical Oncology ResearchSan Diego, California
- Cancer Institute Of FloridaOrlando, Florida
- Palm Beach Cancer InstituteWest Palm Beach, Florida
- Clintell, Inc.Skokie, Illinois
- Cancer Center Of KansasWichita, Kansas
- Kentucky Cancer ClinicHazard, Kentucky
- Annapolis Oncology CenterAnnapolis, Maryland
- Meritus Center For Clinical ResearchHagerstown, Maryland
- North Mississippi Hematology And Oncology Associates, LtdTupelo, Mississippi
- Piedmont Hematology Oncology Associates, PllcWinston-Salem, North Carolina
- North Canton Medical Clinic CenterCanton, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 12, 2015. Always confirm current availability with the study team.